Our data suggest heterogeneity in the management of buprenorphine dosing in the postpartum period. The vast majority (58/66; 88%) of patients either increased or maintained their total daily dose between delivery and 3 months postpartum. These results underscore the importance of an individualized approach to postpartum buprenorphine, factoring in delivery dose, biopsychosocial factors, and risk of return to use and overdose. Future qualitative work is needed to explore the dynamic patient and provider priorities at play in this decision-making.
Woods et al. (Tue,) studied this question.